12 results about "Choroidal neovascularization" patented technology

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention belongs to the technical field of biological medicines, and relates to application of an FGF2 inhibitor in preparation of a medicine for treating retina and choroidal neovascular diseases. An oxygen-induced retinopathy (OIR) mouse model and a novel small molecule compound are used for researching related mechanisms in retinopathy neovascularization, and the treatment effect of the small molecule compound is evaluated. Results show that the Refi-10 disclosed by the invention can be used for treating vascular retinopathy by inhibiting FGF2 targets, and a replacement or supplement method of VEGF (vascular endothelial growth factor) inhibiting drugs is provided.

A method and system for detecting an advanced stage of age-related macular degeneration in a retina. Optical coherence tomography (OCT) imaging data for a retina is received. A presence of choroidal neovascularization (CNV) in the retina is detected, via a machine learning system, using the OCT imaging data. An output that indicates that the presence of CNV in the retina has been detected is generated.

The application discloses a dual-specific antibody with functions of inflammation microenvironment regulation and simultaneous inhibition of choroidal neovascularization, and a preparation method and application thereof. The dual-specific antibody is a single-chain antibody, comprises an IL1R, an IL-1 receptor complex auxiliary subunit IL-1RAcP fragment, and extracellular domains D2 (VEGFR2D2) and D3 (VEGFR2D3) of a tyrosine kinase transmembrane receptor VEGFR2, can simultaneously bind to IL-1 and VEGF, has functions of regulating an inflammation microenvironment and inhibiting choroidal neovascularization, and can more accurately treat fundus-related diseases represented by age-related macular degeneration.

The invention relates to a construction method and application of an animal model with retina geographic atrophy (GA) accompanied by choroidal neovascularization (CNV) symptoms. According to the method, sodium iodate is injected at multiple points in the subretinal space of cynomolgus monkeys, so that the retina has typical and clinically close retinopathy GA and CNV symptoms, and the blank of animal models for preclinical evaluation of multi-target drugs for treating GA and CNV at present is filled.

Disclosed is a method of treating a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. Also disclosed is a method of delaying the progression of vision loss in a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. The methods comprise administering an effective amount of gildeuretinol acetate to the patient.

The invention relates to fluorinated modified aflibercept nano-particles and application thereof in eye drops, and belongs to the technical field of nano-drugs. The fluoridation modified aflibercept nano-particles disclosed by the invention are obtained by coupling a perfluoroalkane chain containing a maleimide group and reduced aflibercept. And due to the hydrophobic and oleophobic characteristics of the fluoroalkane chain and the chemical and biological inertness, the modified aflibercept can quickly cross an eye barrier after being dropped into eyes, and the content of VEGF in the eyes is reduced, so that the non-invasive and efficient treatment of CNV is realized. According to the invention, the administration route of aflibercept is innovated, the treatment of choroidal neovascularization can be realized through a non-invasive route in an eye drop administration mode, and the compliance of a patient is greatly improved.

This application discloses the fusion polypeptide AJ007 and its use, and belongs to the art of ophthalmic drugs. This fusion polypeptide AJ007 is formed by linking a TAT membrane-permeable peptide to the tip of a polypeptide HM-1 molecule that inhibits neovascularization. The fusion polypeptide AJ007 was used in the preparation of polypeptide eye drops, and by selecting the formulation of this application, the fusion polypeptide AJ007 was prepared as an eye drop. In the prevention or treatment of wet age-related macular degeneration, the method of administering eye drops effectively avoids various serious side effects and low patient tolerance problems associated with intravitreal injection in clinical practice, and has the advantage of non-invasive treatment. Furthermore, in a laser-induced mouse wAMD model, it showed extremely good efficacy in improving abnormal hyperplasia of choroidal neovascularization, and possesses high clinical therapeutic potential.

The present application relates to the technical field of medical image processing, and particularly relates to an OCT image choroidal neovascularization segmentation method and system. The present application takes TransUNet as a benchmark network, designs an embedded heterogeneous feature alignment module, a curvature KAN guided attention module and a deep-shallow dual-path decoder to build a choroidal neovascularization segmentation model. Through the heterogeneous feature alignment module, the local features extracted by the convolutional neural network and the global context features extracted by the visual extractor are integrated to enable the network to comprehensively extract the features of the OCT image. Through the curvature KAN guided attention module, the attention mechanism is optimized to better obtain the local geometric features of the image. The deep-shallow dual-path decoder processes deep features and shallow features through two parallel decoding paths respectively, thereby significantly enhancing the network's ability to capture small target lesions. The present application effectively improves the segmentation accuracy of the OCT image choroidal neovascularization.

The application discloses application of SELE in treatment of wet age-related macular degeneration. The application research finds that SELE can significantly promote proliferation, migration and tube formation ability of vascular endothelial cells. SELE By inhibiting gene expression or activity, the application can significantly inhibit choroidal neovascularization in a wAMD mouse model, reduce abnormal vascular leakage, effectively reduce ocular inflammatory response, reduce inflammation-mediated vascular damage, target intervention of biological behavior of vascular endothelial cells, and block a key link of pathological angiogenesis. The application provides a novel molecular target for wAMD treatment and breaks the limitation of the existing anti-VEGF therapy.

The invention discloses an application of SELE in treatment of wet age-related macular degeneration. The research finds that the SELE can obviously promote the proliferation, migration and tube forming ability of vascular endothelial cells. By inhibiting SELE gene expression or activity, choroidal neovascularization in a wAMD mouse model can be significantly inhibited, and abnormal vascular leakage is reduced; meanwhile, the eye inflammatory response is effectively reduced, the inflammation-mediated vascular injury is relieved, the vascular endothelial cell biological behavior is intervened in a targeted manner, and the key link of pathological angiogenesis is blocked. The invention provides a brand new molecular target for wAMD treatment, and breaks through the limitation of the existing anti-VEGF therapy.

The application provides an imino boronic ester structure-based ionizable lipidoid and a preparation method and application thereof in treating mouse choroidal neovascularization, has high mRNA delivery capacity, and is synthesized by a one-pot method of "Ax+By+Cz". The structure has dual sensitivity to slight acidity and ROS, and especially, the lipidoid lipidoid-A4B3C7 can be assembled into a complex with other lipid components and mRNA molecules, and has optimal mRNA delivery efficiency. In addition, in a mouse laser-induced choroidal neovascularization (CNV) model, by single intravitreal injection, an LNP-A4B3C7 co-encapsulated Cas9 mRNA (mCas9) and sgRNA (sgVEGFA) complex targeting a VEGFA gene (LNP-A4B3C7 / mCas9 / sgVEGFA complex) can successfully penetrate into the retinal RPE layer, effectively knock out the VEGFA gene in the RPE cell and significantly reduce the area of the neovascularization. The treatment effect is equivalent to that of the commercial fusion protein Aflibercept. These performances of the lipidoid make it have great development prospects in the field of biomedical materials, especially in the field of gene delivery and gene editing.